Skip to main content
. Author manuscript; available in PMC: 2021 Jul 30.
Published in final edited form as: Mol Pharm. 2019 Dec 27;17(2):392–403. doi: 10.1021/acs.molpharmaceut.9b00589

Figure 6.

Figure 6.

Click-specific capture of small molecules and antibodies at pancreatic tumor sites. (A) Timeline for the tumor-targeting experiment for (A)–(C). Increase in radiant efficiency over tumor ROI’s 24 h after iv DBCO-Cy7 administration. (C) Representative images of intratumoral azide-sNHS ester mice 24 h after iv dose of DBCO-Cy7 fluorophore. (D) Extracted azide-sNHS-infused tumors (top row) and PBS (bottom row) 24 h after iv dosing with DBCO- and Cy7-conjugated anti-PD1 antibody. (E) Quantification of radiant efficiency over tumor and underlying carcass ROI’s 24 h after iv DBCO-Cy7-antibody administration. Samples show mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001 by Student’s t-test. See Supporting Figures 12–14 for full images.